- Home
- MKTX vs GRFS Comparison
MKTX vs GRFS Comparison
Compare MKTX & GRFS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MKTX | GRFS |
|---|---|---|
| Founded | 2000 | 1940 |
| Country | United States | Spain |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.6B | 4.9B |
| IPO Year | 2004 | 2008 |
Fundamental Metrics
Financial Performance| Metric | MKTX | GRFS |
|---|---|---|
| Price | $164.15 | $7.36 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 12 | 2 |
| Target Price | ★ $158.00 | $10.87 |
| AVG Volume (30 Days) | ★ 734.9K | 453.5K |
| Earning Date | 11-06-2026 | 07-28-2022 |
| Dividend Yield | ★ 1.90% | 1.17% |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 4.13 | N/A |
| Revenue | ★ $397,471,000.00 | N/A |
| Revenue This Year | $5.71 | $1.73 |
| Revenue Next Year | $6.80 | $6.26 |
| P/E Ratio | $39.76 | ★ $18.67 |
| Revenue Growth | ★ 7.45 | N/A |
| 52 Week Low | $108.75 | $6.96 |
| 52 Week High | $195.97 | $9.90 |
Technical Indicators
Market Signals| Indicator | MKTX | GRFS |
|---|---|---|
| Relative Strength Index (RSI) | 80.44 | 44.94 |
| Support Level | $163.18 | $7.21 |
| Resistance Level | $165.87 | $8.41 |
| Average True Range (ATR) | 0.34 | 0.11 |
| MACD | -0.51 | 0.01 |
| Stochastic Oscillator | 86.07 | 71.63 |
Price Performance
Historical ComparisonAbout MKTX MarketAxess Holdings Inc.
Founded in 2000, MarketAxess is a leading electronic fixed-income trading platform that connects broker/dealers and institutional investors. The company is primarily focused on credit based fixed income securities with its main trading products being US investment-grade and high-yield bonds, Eurobonds, and Emerging Market corporate debt. Recently the company has expanded more aggressively into Treasuries and municipal bonds with the acquisitions of LiquidityEdge and MuniBrokers in 2019 and 2021, respectively. The company also provides pre- and post-trade services with its acquisition of Regulatory Reporting Hub from Deutsche Börse Group in 2020 adding to its product offerings.
About GRFS Grifols S.A.
Grifols SA is a healthcare company engaged in activities related to plasma-derived products and diagnostic solutions. The group has four reportable segments: Biopharma, Diagnostic, Bio Supplies, and Others. The Biopharma segment focuses on products derived from human plasma for therapeutic use, while the Diagnostic segment includes the marketing of diagnostic testing equipment and reagents. The Bio Supplies segment covers biological products for non-therapeutic use and plasma sales to third parties, and the Others segment includes manufacturing services, research activities, and complementary pharmaceutical products.